RankingsPricing
  1. US-listed companies
  2. CRISPR Therapeutics AG
  3. Financials
  4. Total assets

CRISPR Therapeutics AGCRSP

Market cap
$4.7B
P/E ratio
SummaryFinancials
Period EndTotal assets (Million USD)YoY (%)
Dec 31, 20242,242+0.56%
Dec 31, 20232,230-0.60%
Dec 31, 20222,243-18.49%
Dec 31, 20212,752+50.54%
Dec 31, 20201,828+71.36%
Dec 31, 20191,067+118.14%
Dec 31, 2018489+80.22%
Dec 31, 2017271-21.34%
Dec 31, 2016345

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)